Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years
- DOI
- 10.1177/13524585221083194
- Published
- 2022-04-05
- Container
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1177/13524585221083194,
title = {Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to \>5 years},
author = {Bruce AC Cree and Douglas L Arnold and Robert J Fox and Ralf Gold and Patrick Vermersch and Ralph HB Benedict and Amit Bar-Or and Daniela Piani-Meier and Nicolas Rouyrre and Shannon Ritter and Ajay Kilaru and Goeril Karlsson and Gavin Giovannoni and Ludwig Kappos},
year = {2022},
journal = {Multiple Sclerosis Journal},
doi = {10.1177/13524585221083194},
url = {https://doi.org/10.1177/13524585221083194}
}RIS
TY - JOUR TI - Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years AU - Bruce AC Cree AU - Douglas L Arnold AU - Robert J Fox AU - Ralf Gold AU - Patrick Vermersch AU - Ralph HB Benedict AU - Amit Bar-Or AU - Daniela Piani-Meier AU - Nicolas Rouyrre AU - Shannon Ritter AU - Ajay Kilaru AU - Goeril Karlsson AU - Gavin Giovannoni AU - Ludwig Kappos PY - 2022 JO - Multiple Sclerosis Journal DO - 10.1177/13524585221083194 UR - https://doi.org/10.1177/13524585221083194 ER -
APA
Cree, B. A., Arnold, D. L., Fox, R. J., Gold, R., Vermersch, P., Benedict, R. H., Bar-Or, A., Piani-Meier, D., Rouyrre, N., Ritter, S., Kilaru, A., Karlsson, G., Giovannoni, G., & Kappos, L. (2022). Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years. Multiple Sclerosis Journal. https://doi.org/10.1177/13524585221083194
Source records
- crossref · retrieved 2026-09-26T11:11:06.046Z